Neuro-Oncology Reviews
Volume
28 Number 17
20 June 2026
Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 17, 20 June
Karimi S, Dehpour AR, Hadjighassem M, Khajehnasiri A, Yekta RA,
Aghaei M, Majedi H, Hosseindoost S.
Pyroptosis
as a novel therapeutic target in glioblastoma multiforme:
Mechanisms, molecular insights, and therapeutic potential.
Mol
Ther Nucleic Acids. 2026 Jun 11;37(3):102982. doi:
10.1016/j.omtn.2026.102982. PMID:
42381706. ˍ
Morcos
A, Jung Y, Fuller RN, Jutzy JMS, Wall NR.
Extracellular
Vesicles in Diffuse Midline Glioma: Emerging Mediators of
Radiation Response and Therapeutic Resistance.
Cancers
(Basel).
2026 Jun 13;18(12):1933. doi:
10.3390/cancers18121933. PMID:
42352467. ˍ
Silva
Batista AG, Silva Ribeiro Pereira C, Isgarbose Durello EH, Putini
Vieira AC, Fernandes Junior HJ.
Advances
and challenges in glioblastoma immunotherapy: a meta-analysis of
immune checkpoint inhibitors.
Clin
Transl Oncol.
2026 Jun 13. doi:
10.1007/s12094-026-04453-y. PMID:
42287578. ˍ
Wang
X, Liu W, Sun J, Wei X, Wang Z, Zang L.
Histone
methylation machinery in gliomas: From enzymatic mechanisms to
inhibitor development.
Cancer
Treat Res Commun.
2026 Jun 13;48:101283. doi:
10.1016/j.ctarc.2026.101283. PMID:
42287776. ˍ
Khattak
M, Jadoon I, Umair M, Waqar A, Ullah A, Nisar A, Ahmad J.
Targeting
the tumor microenvironment in glioblastoma: Mechanistic insights,
therapeutic strategies, and advances in immunotherapy.
Life
Sci.
2026 Jun 14;401:124537. doi:
10.1016/j.lfs.2026.124537. PMID:
42289266˰ ˍ
Pollard
SM.
Turning
cancer against itself: Programmable genetic medicines for
glioblastoma.
Mol
Ther.
2026 Jun 15;34(7):3748-3750. doi:
10.1016/j.ymthe.2026.06.006. PMID:
42296959˰ ˍ
Sanikommu
S, Santos AN, Dawoud B, Shah KH, Vazquez S, Shah AH, Lu VM.
Chimeric
Antigen Receptor-T Cell Therapy for Pediatric and Young Adult
Primary Central Nervous System Tumors: A Systematic Review of
Early Phase Clinical Trials with a Focus on Diffuse Midline
Glioma.
Target
Oncol.
2026 Jun 15. doi:
10.1007/s11523-026-01225-0. PMID:
42295570. ˍ
Hammond
A, Paolini L, Sabet CJ, Garg S, Jadav AA, Arkalgud A, Ranganathan
S, Kohli K, Jain U, Peruzzi P, Messina R, Umana GE, Ghashghaie G,
Shah S, Zhamkochyan A, Mezgebu Bawoke M, Jain B.
Neurosurgical
Care in Italy: A Comprehensive Review and Lessons for High-Income
Nations.
Neurosurg
Pract.
2026 Jun 16;7(3):e000252. doi:
10.1227/neuprac.0000000000000252. PMID:
42305410. ˍ
Kang
KD, Zhang Z, Bernstock JD, Friedman GK.
Oncolytic
viruses enhance CAR-T activity for the treatment of pediatric
diffuse midline gliomas.
Mol
Ther Oncol.
2026 Jun 16;34(3):201255. doi:
10.1016/j.omton.2026.201255. PMID:
42358379. ˍ
Zhou
L, Luo X, Bao T, Sun H, He C, Yang Y, Xia Y.
Neurobiology
of cancer: Unraveling the roles of the nervous system in tumor
initiation, progression, and therapeutic.
Chin
Med J (Engl).
2026 Jun 16. doi:
10.1097/CM9.0000000000004144. PMID:
42299464. ˍ
Al-Saidi
N, Mohammed D, Fatima Z, Bangash AH, Murthy SG, Gelfand Y, Yassari
R, De la Garza Ramos R.
Minimally
invasive approaches to intramedullary spinal cord tumors: a
systematic review of techniques and outcomes.
Eur
Spine J.
2026 Jun 17. doi:
10.1007/s00586-026-10084-2. PMID:
42303793. ˍ
Lehmann
U.
Clinical
diagnostic utility of MGMT
promoter
methylation.
Epigenomics.
2026 Jun 17:1-12. doi:
10.1080/17501911.2026.2688974. PMID:
42307140˰ ˍ
Wu
B, Duan R, Tu R, Luo M, Ge L, Chen C, Lu M.
Trends
in Ubiquitination Research in Brain Diseases from 1999 to 2024: A
Bibliometric Analysis.
Curr
Med Chem.
2026 Jun 17. doi:
10.2174/0109298673404276260224052525. PMID:
42316494. ˍ
Sayed
U, Alieva R, Hanumanthayya M, Singhal D, Panigrahi R, Tailor NK,
Buzrukov T, Norkulov S.
MGMT
promoter methylation across glioma subtypes: biological relevance,
treatment response, and survival outcomes.
Mol
Biol Rep.
2026 Jun 18;53(1):955. doi:
10.1007/s11033-026-12169-z. PMID:
42313202˰ ˍ
Jia
B, Zhao L, Tang M, Xie N, Huang Y, Liang X, Yang G, Wu Q, Sun Z,
Kwan HY, Sun H, Xu K.
Neuron-tumor
crosstalk in cancer: molecular mechanisms and translational
advances.
Mol
Cancer.
2026 Jun 19. doi:
10.1186/s12943-026-02715-5. PMID:
42321740. ˍ
Mikołajczak
K, Chmiel J, Leszek J.
Neuroinflammation
in Alzheimer's Disease (AD) and Glioblastoma (GBM): Shared
Mechanisms and Therapeutic Insights.
Cells.
2026 Jun 19;15(12):1111. doi:
10.3390/cells15121111. PMID:
42346137. ˍ
Nuss
ZJ, DeYoung C, Gross D.
H3K27M-mutant
diffuse midline glioma pharmacotherapy: Clinical evidence and
practice implications of dordaviprone.
J
Oncol Pharm Pract.
2026 Jun 19:10781552261461529. doi:
10.1177/10781552261461529. PMID:
42317168˰ ˍ
Tanzhu
GL, Chen L, Ning JY, Xiao G, Wen S, Wang C, Wen H, Zhang KQ, Yang
J, Jia MY, Deng HB, Marti TM, Lockman PR, Zhou RR.
Crosstalk
in the brain tumor microenvironment: mechanisms, therapeutic
strategies, and clinical advances.
Mil
Med Res. 2026 Jun 20;13(1):100047. doi:
10.1016/j.mmr.2026.100047. PMID:
42375809. ˍ